We are live on ! Find out more
FOMX

Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX

Delisted

FOMX was delisted on the 6th of March, 2020.

72 hedge funds and large institutions have $143M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2015 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 30 increasing their positions, 17 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

76% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 17

13% more capital invested

Capital invested by funds: $127M → $143M (+$16.7M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

6% less funds holding

Funds holding: 7772 (-5)

33% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 12

Holders
72
Holders Change
-5
Holders Change %
-6.49%
% of All Funds
1.89%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
8
Increased
30
Reduced
17
Closed
12
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
CS
51
Credit Suisse
Switzerland
$165K +$68K +9,092 +82%
VanEck Associates
52
VanEck Associates
New York
$123K +$16.5K +2,213 +17%
NFA
53
Nationwide Fund Advisors
Ohio
$118K
PPCM
54
Pillar Pacific Capital Management
California
$114K
AIG
55
American International Group
New York
$107K -$172 -23 -0.2%
Citigroup
56
Citigroup
New York
$90K +$82.7K +11,066 +276,650%
VOYA Investment Management
57
VOYA Investment Management
Georgia
$89K
BA
58
BlackRock Advisors
Delaware
$49K -$39.6K -5,299 -47%
Bank of America
59
Bank of America
North Carolina
$44K +$40.1K +5,372 +6,715%
BNP Paribas Financial Markets
60
BNP Paribas Financial Markets
France
$37.2K -$4.53K -606 -12%
GWM
61
Gupta Wealth Management
California
$24K
UBS Group
62
UBS Group
Switzerland
$15K +$2.49K +333 +23%
PCM
63
Penserra Capital Management
California
$14K +$13.3K +1,782 New
Victory Capital Management
64
Victory Capital Management
Texas
$13K +$635 +85 +6%
TRCT
65
Tower Research Capital (TRC)
New York
$11K -$32.7K -4,380 -76%
LTFS
66
Ladenburg Thalmann Financial Services
Florida
$8K -$3.74K -500 -33%
BlackRock
67
BlackRock
New York
$5K
MTIP
68
Magee Thomson Investment Partners
California
$5K +$830 +111 +21%
Barclays
69
Barclays
United Kingdom
$4K +$3.13K +419 +355%
IA
70
IFP Advisors
Florida
$2K +$1.5K +200 New
Royal Bank of Canada
71
Royal Bank of Canada
Ontario, Canada
$1K -$7.69K -1,029 -93%
Manulife (Manufacturers Life Insurance)
72
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$120
PHS
73
PFM Health Sciences
California
-$3.72M -506,920 Closed
EI
74
EAM Investors
California
-$1.6M -218,200 Closed
FCM
75
Farallon Capital Management
California
-$1.25M -170,900 Closed

FOMX Hedge Fund Activity: Q4 2015 in Review

72 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q4 2015, worth a combined $143M — up 13% from $127M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of FOMX and 8 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 30 added.

The largest buyer was Senzar Asset Management, adding an estimated $4.73M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $3.72M sold.

  • 72 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q4 2015, down from 77 in Q3 2015.
  • Funds reported $143M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q4 2015, up 13% quarter-over-quarter.
  • 8 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q4 2015 and 12 closed out, a net change of -4 holders.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q4 2015 was Senzar Asset Management, an estimated $4.73M added.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q4 2015 was PFM Health Sciences, an estimated $3.72M sold.

Based on aggregated 13F filings for Q4 2015.